| Literature DB >> 31325289 |
Sarah K Moore1, Jacob T Borodovsky2, Lisa A Marsch1, Michael Grabinski1, Sarah Bessen3.
Abstract
BACKGROUND: The unprecedented number of youths engaged in nonmedical use of prescription opioids (POs), as well as the myriad negative consequences of such misuse, emphasizes the importance of prevention efforts targeting this public health crisis. Although there are several science-based, interactive drug abuse prevention programs focused on preventing the use of nonprescription drugs in youths, to our knowledge, there are no science-based interactive programs that focus on the prevention of PO abuse among adolescents.Entities:
Keywords: adolescent; internet; opioids; prevention and control; randomized controlled trial
Year: 2019 PMID: 31325289 PMCID: PMC6676791 DOI: 10.2196/12389
Source DB: PubMed Journal: JMIR Form Res ISSN: 2561-326X
Overview of aims and participant activities by phase.
| Small Business Technology Transfera Phase – Aim | Primary aims | End user activity | Eligibility criteria | Sample size (n) |
| I – 1. (2010-2011) | Develop pilot content of a Web-based POb abuse prevention program for High school-aged Youth | FGc 1 | Youth 14-18: not in substance abuse treatment / opioid naive | 6 |
| FG 2 | Youth 14-18: in treatment for wider substance abuse issue | 5 | ||
| FG 3 (Interview)d | Youth 14-18: in treatment for opioid dependence | 1 | ||
| Individual feedback sessions | Youth 14-18: along a continuum of exposure to opioids (paralleling groups from FG 1, 2 and Interview) | 30 | ||
| II – 1. (2014-2016) | Complete development of ALL components of a Web-based PO abuse prevention program/Integrate all components into a unified, Internet-based multimedia package to be run cross-platform | FG 1 | Youth 12-19e: in treatment for prescription opioid dependence | 8 |
| FG 2 | Youth 12-17f: not in substance abuse treatment/ opioid naïve | 6 | ||
| FG 3 | Youth 12-17: prescribed an opioid in the past year | 4 | ||
| Writing sessions | Youth in treatment for opioid dependence | 30 | ||
| Individual feedback sessions | Youth 12-19: along a continuum of exposure to opioids (paralleling groups from FG 4, 5 and 6) | 27 | ||
| II – 2. (2017-2018) | Conduct a randomized, controlled trial to evaluate the effectiveness of a Web-based PO abuse prevention program | Randomized, controlled trial | Youth 12-17, English literate, whose parents provide consent (w/ access to Internet) | 400 (planned) |
aA program that expands funding opportunities in the federal innovation research and development arena.
bPO: prescription opioid.
cFG: focus group.
dWe were able to recruit only 1 adolescent who met the eligibility criteria and consequently conducted an in-depth interview instead of a focus group.
eThe eligible age range was broadened for youth in treatment for PO dependence due to the fact that most youth do not enter treatment for opioid dependence before 16 years of age.
fThe target age range for Phase I (14-18) was determined to be too old in light of scientific literature related to prescription opioid misuse among youth published between the funding of Phases I (2010) and II (2014). In the interests of (1) locating our work within the larger corpus of effective prevention efforts targeting adolescent substance abuse in general (Hale et al, 2014), (2) attending to epidemiological work (Meier et al, 2012) cautioning against designing prevention initiatives that focus on the later high school years, and (3) seeking to help youth on the younger tail of initiation of prescription opioid abuse avoid the potentially significant negative long-term consequences of early experimentation (McCabe, 2007), we adjusted the range to youth between the ages of 12-17 for Phase II.
Program development participant’ demographic characteristics.
| Characteristic | Phase I | Phase II | ||||
| Focus groups #1-3 (n=12) | Feedback sessions (n=30) | Focus groups #1-3 (n=18) | Feedback sessions (n=27) | Writing sessions (n=30) | ||
| Age (years), mean (SD) | 16 | 16.53 (1.1) | 16.77 (2.2) | 16.37 (2.2) | 21.83 (2.0) | |
| Female | 5 (42) | 13 (43) | 11 (61) | 11 (41) | 9 (30) | |
| Male | 7 (58) | 17 (57) | 7 (39) | 16 (59) | 21 (70) | |
| Non-Hispanic | —a | 27 (90) | 16 (89) | 26 (96) | 13 (87)b | |
| White | — | 15 (50) | 15 (83) | 24 (88) | — | |
| Black | — | 6 (20) | — | 1 (4) | — | |
| Mixed/other | — | 9 (30) | 3 (17) | 2 (8) | — | |
| Previous experience w/ POc Drug Prevention Program, n (%) | 1 (7) | 1(3) | — | 1 (4) | — | |
| Age at first PO use, mean (SD) | — | — | 14.7 (1.2)d | — | 15.75 (2.4) | |
| Transition from PO heroin use, n (%) | — | — | 6 (86)d | — | 12 (41) | |
aData not collected.
bDenominator is 15.
cPO: prescription opioid.
dApplies only to youth in focus group #1 (n=8).
Figure 1Pre- and postknowledge test scores: Phases 1 and 2 (P1, P2).
Figure 2Feedback survey results.